Pan-Cancer Drivers of Metastasis Unveiled: A Breakthrough for Cancer Treatment

Cancer metastasis—the spread of cancer to other organs—is the primary reason cancer patients succumb to the disease. A recent study led by Professor Vijay Tiwari at the University of Southern Denmark has identified a “genetic signature” comprising 177 genes common across various cancer types that facilitates this deadly process.

Professor Tiwari explains, “Our research has uncovered critical pan-cancer drivers of metastasis, enhancing our understanding of cancer progression and opening doors to innovative therapeutic strategies.”

Key Genetic Findings

The study highlights two significant genes:

• SP1, which accelerates metastasis.
• KLF5, which helps to suppress it.

These findings challenge the notion that metastasis mechanisms differ significantly between various cancers. This genomic insight offers a promising path for developing treatments effective for a broad range of cancer patients, irrespective of their specific diagnosis.

New Hope for Early Diagnosis and Treatment

The research has the potential to predict a patient’s risk of metastasis accurately. By analyzing the 177-gene signature in a tumor, doctors can determine the likelihood of cancer spreading early and intervene accordingly.

Vijay Tiwari elaborates, “This could save lives for patients whose cancers are detected before they metastasize to critical organs. Early interventions using repurposed drugs identified in the study could disrupt metastasis before it becomes life-threatening.”

One example highlighted in the study is Vorinostat, an existing FDA-approved drug, which shows potential as a treatment to block metastasis. Tiwari adds, “Repurposing approved drugs could make these treatments accessible to patients much sooner than if entirely new medications were developed.”

Ryan Lusby from Queens University Belfast, the lead author, emphasizes, “Discovering common principles of metastasis across different cancers and identifying biomarkers for metastasis and new drugs that can be applied to a wide range of cancers is remarkable.”

Why This Matters to Cancer Patients

This discovery has far-reaching implications for cancer care:

• Broader Treatment Options: Targeting shared genetic drivers could lead to therapies effective across multiple cancer types.
• Faster Drug Access: Repurposing existing medications could expedite the delivery of new treatments to patients.
• Personalized Risk Assessment: Doctors could tailor treatments based on a patient’s specific risk of metastasis.

These findings signal a shift in how cancer is understood. Instead of focusing solely on cancer types, treatments may increasingly target shared genetic vulnerabilities, benefiting a greater number of patients.

Dr. Engin Demirdizen, a co-author, notes, “As metastasis progresses, tumor cells and their microenvironment engage in increasingly dynamic communication through WNT signaling, driven by the transcription factor SP1.”

Dr. Mohammed Inayatullah adds, “We are thrilled to showcase how genomics has enabled us to repurpose existing drugs for cancer therapy.”

A Breakthrough for Families and Society

Understanding and targeting the genetic triggers of metastasis provides a lifeline for patients and their families, offering longer, healthier lives and reducing the emotional and financial burden associated with advanced cancer.

The Method Behind the Discovery

Purpose: The study analyzed over 200 tumors from six different cancer types to find universal genetic drivers of metastasis and develop better diagnostic tools and treatments.

Technique: Researchers used advanced single-cell RNA sequencing (scRNA-seq) to examine individual cancer cells from both metastatic and non-metastatic tumors.

Findings: A 177-gene signature consistent with metastasis across cancer types was identified.

Experiments: Key genes, SP1 (promotes metastasis) and KLF5 (suppresses metastasis), were tested by disrupting their function in lab and animal models.

Software and Medicine: Advanced computational tools identified existing drugs like Vorinostat as potential therapies to block metastasis.

While this method represents a critical step toward future cancer treatments, further human studies are needed to validate these findings.

Disclaimer: This content has been prepared by Archynetys for informational purposes only and should not be considered medical advice.